A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

1992434 citationsJournal Article

Authors

CPT-11 is a very active agent for NSCLC with acceptable toxicities. Further trials in combination with other agents for this disease are warranted.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 10, Issue 1, pp. 16-20

Field-Weighted Citation Impact: 9.81